# AI Platform for Pharmaceutical & Biotech

> Source: https://ibl.ai/resources/enterprise/pharmaceuticals


*Own the source code. Deploy autonomous agents. Protect your IP. Built for GxP, FDA 21 CFR Part 11, and the most regulated environments in the world.*

ibl.ai is a production-grade AI platform serving 1.6M+ users across 400+ organizations — delivered as full source code, not a SaaS subscription. Pharmaceutical and biotech organizations receive the complete codebase, deploy it on their own infrastructure, and operate it with zero external dependencies.

This is not a pilot project or a proof of concept. It is a validated, production platform that powers AI at scale for NVIDIA, Kaplan, and leading global institutions — now purpose-built for the compliance, IP protection, and data integrity demands of pharma and biotech.

From autonomous agents that monitor clinical trial deviations to AI-driven regulatory document generation and GxP training compliance, ibl.ai gives your organization the infrastructure to move faster without compromising the auditability, security, or control that FDA and EMA regulations demand.

## A Production Platform, Not a Project

### Production-Proven at Scale

1.6M+ users across 400+ organizations including NVIDIA, Kaplan, and Syracuse University. This platform has been stress-tested in production environments — not assembled for a demo.

### Full Source Code Delivered to You

You receive the complete codebase. No black-box SaaS. No runtime dependencies on ibl.ai servers. Your legal, compliance, and engineering teams can audit, validate, and modify every line.

### Deploy Anywhere — Including Air-Gapped

Run on your private cloud, on-premise data center, or fully air-gapped environment. Zero data leaves your perimeter. Ideal for environments governed by FDA 21 CFR Part 11 and GxP requirements.

### Model-Agnostic Architecture

Works with Claude, GPT-4, Gemini, Llama, Mistral, or your own fine-tuned models. Swap or upgrade models without rebuilding your platform. No model vendor lock-in.

### No Vendor Lock-In — Ever

If you never call us again, the system keeps running. You own the platform, the data, the agents, and the infrastructure. No license renewals. No forced upgrades. No dependency.

### Complete Audit Trail for Every Agent Action

Every agent decision, action, API call, and data query is logged and reviewable. Built for environments where auditability is not optional — it is a regulatory requirement.

## AI Agent Use Cases

### Autonomous Regulatory Document Agent

Agents autonomously draft, review, and cross-reference regulatory submissions — CTDs, INDs, NDAs — by querying internal document repositories, applying current FDA and EMA guidance, and flagging inconsistencies before human review. Agents do not wait to be asked; they monitor document pipelines and act.

**Impact:** Reduce regulatory document preparation time by up to 60%, cutting submission cycles from weeks to days.

### Clinical Trial Deviation Monitor

Autonomous agents continuously monitor trial data feeds, protocol adherence logs, and site reports. When a deviation threshold is crossed, agents classify severity, generate CAPA documentation drafts, notify responsible parties, and log the full action chain — without human initiation.

**Impact:** Detect and escalate protocol deviations up to 10x faster than manual review cycles, reducing trial risk exposure.

### GxP Training Compliance Agent

Agents track training completion across roles, sites, and SOPs. When a qualification gap is detected — new SOP release, role change, expiring certification — agents automatically assign training, send escalations, and update compliance records. Full audit trail maintained for inspection readiness.

**Impact:** Achieve 98%+ GxP training compliance rates and reduce audit preparation time by 40%.

### Drug Discovery Literature & Data Agent

Agents autonomously scan PubMed, internal research databases, and patent repositories to surface relevant findings, identify compound interactions, and synthesize competitive intelligence reports. Agents execute searches, analyze results, and deliver structured summaries — not search links.

**Impact:** Compress literature review cycles from days to hours, accelerating early-stage discovery timelines.

### Pharmacovigilance Signal Detection Agent

Agents monitor adverse event databases, incoming safety reports, and post-market surveillance data in real time. When a potential safety signal emerges, agents correlate across data sources, generate preliminary signal assessment reports, and route to the appropriate safety officer with full evidence chains.

**Impact:** Reduce signal detection lag by up to 70%, improving post-market safety response times.

### Validated System Onboarding & Training Agent

MentorAI-powered agents deliver role-specific onboarding for clinical, regulatory, and manufacturing staff — adapting content to the learner's role, site, and current SOP version. Agents track competency, flag gaps, and generate training records compliant with 21 CFR Part 11 electronic signature requirements.

**Impact:** Reduce new hire time-to-competency by 35% while maintaining full electronic training record compliance.

## Security & Deployment

- **Air-Gapped Deployment:** The entire platform runs on your infrastructure with zero external network dependencies. No calls to ibl.ai servers, no cloud telemetry, no external model APIs required. Suitable for the most sensitive research and clinical environments.
- **Zero Telemetry — No Data Leaves Your Perimeter:** We collect nothing. No usage analytics, no prompt logging, no model inference data is transmitted externally. Your compound data, trial data, and patient-adjacent information never leave your environment.
- **Complete Audit Trail for 21 CFR Part 11 Compliance:** Every agent action, user interaction, content access, and system event is logged with immutable timestamps and user attribution. Audit logs are exportable and structured for regulatory inspection and validation documentation.
- **Role-Based Access Control & Multi-Tenant Isolation:** Granular RBAC ensures clinical staff, regulatory teams, manufacturing, and external CRO partners each operate in isolated environments with appropriate data access. Multi-tenant architecture prevents cross-contamination of sensitive data.
- **Full Source Code Auditability:** Your security and validation teams receive the complete source code. Every authentication mechanism, data flow, and agent behavior can be independently audited, validated, and documented for IQ/OQ/PQ processes.
- **Electronic Signature & Record Compliance:** Platform architecture supports 21 CFR Part 11 electronic signature requirements. Training completions, agent-generated documents, and approval workflows can be configured with compliant e-signature controls.

## ROI & Impact

| Metric | Value | Description |
|--------|-------|-------------|
| Regulatory Submission Preparation | 60% faster | Autonomous agents drafting, cross-referencing, and reviewing regulatory documents reduce submission preparation cycles from weeks to days, directly compressing time-to-approval timelines. |
| GxP Training Compliance Rate | 98%+ | Automated training assignment, escalation, and record-keeping driven by compliance agents eliminates manual tracking gaps and sustains near-perfect compliance rates across sites and roles. |
| Clinical Trial Deviation Response Time | 10x faster | Continuous autonomous monitoring and automated CAPA initiation reduces the time from deviation detection to escalation from days to minutes, reducing trial risk and potential FDA findings. |
| Audit Preparation Time | 40% reduction | Immutable audit trails, automated training records, and agent action logs mean inspection-ready documentation is always current — eliminating the manual scramble before regulatory audits. |
| Drug Discovery Literature Review | 80% time reduction | Autonomous literature and data agents compress multi-day manual review cycles to hours, accelerating early-stage discovery and competitive intelligence workflows without adding headcount. |

## FAQ

**Q: Can ibl.ai be deployed in a fully air-gapped environment with no internet connectivity?**

Yes. The platform is designed for air-gapped deployment with zero external dependencies. No calls are made to ibl.ai servers, no telemetry is transmitted, and the platform can run entirely on your private infrastructure using on-premise or locally hosted AI models. This makes it suitable for the most sensitive pharmaceutical research and regulated manufacturing environments.

**Q: How does ibl.ai support FDA 21 CFR Part 11 compliance?**

ibl.ai delivers full source code, enabling your validation team to execute independent IQ/OQ/PQ protocols against the actual system — not a vendor black box. Every agent action, user interaction, and system event is logged with immutable, timestamped audit records. RBAC, configurable e-signature workflows, and complete data residency control directly support 21 CFR Part 11 requirements. We also support validation documentation as part of the delivery process.

**Q: What is the difference between ibl.ai's autonomous agents and a standard AI chatbot for pharma use cases?**

Chatbots respond to questions. ibl.ai autonomous agents execute workflows. A regulatory agent doesn't just answer questions about submission requirements — it monitors your document pipeline, drafts CTD sections by querying your internal repositories, cross-references current FDA guidance, flags inconsistencies, and routes for review. Agents act, log every action, and operate continuously — not just when prompted.

**Q: How is our proprietary research data and compound IP protected?**

Your data never leaves your environment. The platform is deployed on your infrastructure, and zero telemetry is transmitted externally. You own the source code, so there is no shared infrastructure, no vendor data access, and no risk of your compound libraries, clinical protocols, or regulatory strategies being exposed through shared model training or SaaS logging. Air-gapped deployment is available for maximum IP protection.

**Q: Can ibl.ai integrate with our existing CTMS, LIMS, and EDC systems?**

Yes. ibl.ai uses MCP (Model Context Protocol) and a RESTful API-first architecture to connect agents to your existing systems — CTMS, LIMS, EDC platforms, document management systems, and regulatory databases. Agents can query, write, and act across these systems as part of autonomous workflows. Integration is configured during the joint development phase with your IT and clinical operations teams.

**Q: What happens to our platform if we stop working with ibl.ai?**

Nothing changes. You own the source code and the infrastructure. The platform continues to operate exactly as deployed. There is no license server to check in with, no API key that expires, and no forced upgrade cycle. This is a deliberate design principle — we believe your validated, regulated systems should never be held hostage to a vendor relationship.

**Q: Which AI models does the platform support, and can we use a private or fine-tuned model?**

ibl.ai is fully model-agnostic. The platform works with Claude, GPT-4, Gemini, Llama, Mistral, and custom fine-tuned models. For air-gapped pharmaceutical deployments, locally hosted open-source models such as Llama or Mistral are commonly used. You can swap or upgrade models without rebuilding agent logic or workflows, and you are never locked into a single model vendor.

**Q: How does ibl.ai handle GxP training compliance and training record management?**

The MentorAI and Agentic LMS products deliver role-specific GxP training with autonomous compliance tracking. Agents monitor training completion against current SOP versions and role requirements, automatically assign training when gaps are detected, escalate overdue completions, and maintain electronic training records structured for regulatory inspection. Records include timestamps, completion evidence, and assessments — supporting 21 CFR Part 11 and GxP data integrity requirements.